title: Metabolite analysis distinguishes between mice with epidermolysis bullosa acquisita and healthy mice.
abstract: BACKGROUND
  Epidermolysis bullosa acquisita (EBA) is a rare skin blistering disease with a prevalence of 0.2/ million people. EBA is characterized by autoantibodies against type VII collagen. Type VII collagen builds anchoring fibrils that are essential for the dermal-epidermal junction. The pathogenic relevance of antibodies against type VII collagen subdomains has been demonstrated both in vitro and in vivo. Despite the multitude of clinical and immunological data, no information on metabolic changes exists.
  
  
  METHODS
  We used an animal model of EBA to obtain insights into metabolomic changes during EBA. Sera from mice with immunization-induced EBA and control mice were obtained and metabolites were isolated by filtration. Proton nuclear magnetic resonance (NMR) spectra were recorded and analyzed by principal component analysis (PCA), partial least squares discrimination analysis (PLS-DA) and random forest.
  
  
  RESULTS
  The metabolic pattern of immunized mice and control mice could be clearly distinguished with PCA and PLS-DA. Metabolites that contribute to the discrimination could be identified via random forest. The observed changes in the metabolic pattern of EBA sera, i.e. increased levels of amino acid, point toward an increased energy demand in EBA.
  
  
  CONCLUSIONS
  Knowledge about metabolic changes due to EBA could help in future to assess the disease status during treatment. Confirming the metabolic changes in patients needs probably large cohorts.
authors.affiliation: Excellence Cluster Inflammation at Interfaces, Schleswig-Holstein, Germany.
authors.forename: Sarah
authors.initials: S
authors.lastname: Schönig
authors.forename: Andreas
authors.initials: A
authors.lastname: Recke
authors.forename: Misa
authors.initials: M
authors.lastname: Hirose
authors.forename: Ralf J
authors.initials: RJ
authors.lastname: Ludwig
authors.forename: Karsten
authors.initials: K
authors.lastname: Seeger
mesh_terms: D000818:Animals; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D001786:Blood Glucose / Q000032:analysis; D024143:Collagen Type VII / Q000008:administration & dosage / Q000276:immunology*; D020405:Dermis / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D004817:Epidermis / Q000276:immunology / Q000378:metabolism; D016107:Epidermolysis Bullosa Acquisita / Q000209:etiology / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology*; D006801:Humans; D007532:Isoleucine / Q000097:blood; D007785:Lactose / Q000097:blood; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D055432:Metabolomics / Q000379:methods*; D051379:Mice; D011392:Proline / Q000097:blood; D012867:Skin / Q000276:immunology / Q000378:metabolism / Q000473:pathology
chemical_list: D001323:Autoantibodies; D001786:Blood Glucose; D024143:Collagen Type VII; D007532:Isoleucine; D011392:Proline; D007785:Lactose